Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab

We report cumulative safety and 48-month efficacy results from PRIME. Amyloid-related imaging abnormalities-edema (ARIA-E) were the most common adverse event (AE); 61% of participants with ARIA-E were asymptomatic. Dose titration was associated with a decrease in the incidence of ARIA-E. Aducanumab decreased levels of amyloid beta (Aβ) in a dose- and time-dependent manner.PMID:38567735 | DOI:10.1002/alz.13755

Source: The Journal of Alzheimers Association - April 3, 2024 Category: Psychiatry Authors: Tianle Chen John O'Gorman Carmen Castrillo-Viguera Rajasimhan Rajagovindan Gioacchino G Curiale Ying Tian Dakshaben Patel Philipp von Rosenstiel Christian von Hehn Stephen Salloway Christoph Hock Roger M Nitsch Samantha Budd Haeberlein Alfred Sandrock Pri Source Type: research